🇺🇸 FDA
Patent

US 11053484

Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene

granted A61KA61K40/11A61K40/31

Quick answer

US patent 11053484 (Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene) held by Precision BioSciences, Inc. expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/32, A61K40/40